Bristol Myers Squibb acquired Turning Point Therapeutics, a leading precision oncology company, for USD 76.00 per share. The acquisition expanded Bristol Myers Squibb's portfolio of cancer drugs and pipeline.
Bristol Myers Squibb announced a definitive agreement to acquire Mirati Therapeutics, Inc. for USD 58.00 per share. The acquisition expanded Bristol Myers Squibb's portfolio of cancer drugs and pipeline, particularly in the area of KRAS-mutated cancer.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 5401
Published Date: Nov 27, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Increasing demand for healthcare sector is the major factor driving the market growth.
The market size of muscle invasive bladder cancer is anticipated to attain a CAGR of 10% over the forecast period, i.e., 2024-2036.
The major players in the market Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., AstraZeneca PLC, Johnson & Johnson, Novartis International AG, and others.
The hospitals segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.
The market in the Asia Pacific region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.